http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
인간 자궁상피와의 공동배양이 미성숙 생쥐난자의 체외 성숙 및 초기 배아발달에 미치는 영향
김광례(KR Kim),문신용(SY Moon),장윤석(YS Chang) 대한산부인과학회 1995 Obstetrics & Gynecology Science Vol.38 No.6
The use of superovulation for human in vitro fertilization-embryo transfer (IVF-ET) produces a cohort of oocytes that can be of varing levels of maturity. Mature oocytes are incubated for 5 to 6 hours before sperm insemination, whereas immature oocytes are cultured for 20 to 36 hours before they are inseminated, but the fertilization rate for immature oocytes matured in vitro remains below than those achieved with mature oocytes. There have been reported that successful in vitro maturation of animal oocytes were achieved by culture alone, by adding gonadotropins or specific growth factors to that medium, or by coculture on the top of granulosal cells. To increase the fertilization and early embryo development, immature oocyte of mouse (ICR) were cocultrued with human uterine epithelial cells isolated from uterine stromal cells by highly purified method. The coculture system improved in vitro maturation of immature mouse oocyte by full expansion of cumulus cells(86% vs 41.5%) and extrusion of first polar body(58% vs 45.4%) in comparison with medium alone. The fertilization rates(58% vs 32.8%) and embryo cleavage rate (20.2% vs 9.2%) of in virto maturated immature oocyte were improved in coculture system. When mouse 1-cell embryo were coclutured on the top of monolayer of human uterine epithelial cells, embryo development rates(>4 cell embryo) were significantly higher than control group (45.4% vs 16.6%). The in vitro fertilization rates of mature oocytes(87.2% vs 79.9%) were increased in coculture system that showed good quality of embryo in subsequent embryo development, reducing in fragmentation(3.1% vs 26%). In conclusion, when cocultured with mouse immature oocytes, mature oocyte, and early embryos, human utreine epithelial cells improved the rate of in vitro maturation of oocyte, fertilization and early embryo development, respectively. This suggests that application of a permanent established stable endometrial cell line to assisted reproductive techniques may allow better results in selection of embryo for transfer therefore impove the following pregnancy.
폐경 후 여성의 에스트로젠 보충요법시 병합 투여된 프로제스테론이 골밀도에 미치는 영향
채희동,김광례,서창석,최영민,김석현,신창제,김정구,문신용,이진용 대한폐경학회 1997 대한폐경학회지 Vol.3 No.1
It is well established that estrogen replacement therapy prevents the bone loss associated with postmenopausal state. And progestogens used alone, given in larger amount than that in estrogen replacement therapy, have been shown to reduce the postmenopausal bone loss. However, the impacts of added progestogen during estrogen replacement therapy on the bone mineral densities(BMD) are not well known. For this purpose, we analysed the changes in BMD of 104 postmenopausal women who underwent estrogen replacement therapy at least for 12 months: 36 women received estrogen only(Premarin 0.625mg/day), 41 women received estrogen with cyclic addition of progestogen(medroxyprogesterone, MPA, 10mg/day for 12 days per month), 27 women received estrogen with daily addition of progestogen(MPA 2.5mg daily). Our data revealed that continuous use of MPA in addition to estrogen for one year significantly increased the BMD of lumbar spines(L2-4) by 7.6±1.9% compared to that of before treatment while therapy with estrogen only did not(1.7±1.0%). Also cyclic addition of MPA for one year increased the BMD of lumbar spines by 6.2±1.3% compared to that of before treatment. And the increases in BMD of lumar spines derived from continuous or cyclic use of MPA in addition to estrogen were significantly greater than that from therapy with estrogen only. There was no significant difference in increases in BMD of lumbar spines between cyclic use and continuous use of MPA. And there was no significant difference in increases in BMD of femur neck among three groups. The patients who showed a decrease in BMD by more than 3% at 12 months of treatment compared to pretreatment were as follows: In BMD of lumbar spines, 16.7%(6/36) in therapy with estrogen-only, 2.4%(1/41) in the cyclic use of MPA, 3.7%(1/27) in the continuous use of MPA; In BMD of femur neck, 25.0%(9/36) in therapy with estrogen-only, 22.0%(9/41) in the cyclic use of MPA, 11.1%(3/27) in the continuous use of MPA. The unine calcium/creatinine ratio decreased during therapy in all gropus without a significant difference among three groups. These data showed that added progestogen(MPA) during estrogen replacement therapy significantly increased the bone mineral densities(BMD) of lumbar spines, and suggest that the continuous combined regimen of estrogen and progestogen may be the regimen of choice for the prevention or treatment of postmenopausal osteoporosis
체외수정시술시 배아의 보조부화술을 이용한 임신율 향상에 관한 연구
김석현,김광례,채희동,이재훈,김희선,류범용,오선경,서창석,최영민,김정구,문신용,이진용,Kim, Seok-Hyun,Kim, Kwang-Rye,Chae, Hee-Dong,Lee, Jae-Hoon,Kim, Hee-Sun,Ryu, Buom-Yong,Oh, Sun-Kyung,Suh, Chang-Suk,Choi, Young-Min,Kim, Jung-Gu,Moon, S 대한생식의학회 1997 Clinical and Experimental Reproductive Medicine Vol.24 No.1
In spite of much progress in vitro fertilization and embryo transfer (IVF-ET) program, the pregnancy rate remains at 20-30%, and the endometrial implantation rate per embryo transferred at 10-15%. As a result, about 90% of embryos may fail to implant to the endometrium, and many attempts such as optimization of follicular development, improvement of in vitro culture system including coculture, and micromanipulation of zona pellucida have been made to improve embryonic implantation after IVF-ET. Recently, several procedures of assisted hatching (AH) using micromanipulation have been introduced, and pregnancies and births have been obtained after AH. To develop and establish AH as an effective procedure to improve embryonic implantation, AH with partial zona dissection (PZD) was performed in 116 cycles of 89 infertile couples who had previous repeated failures of standard IVF-ET more than two times (Group I: 71 cycles in 54 patients), or who had implantation failure of embryos with good quality (Group II: 15 cycles in 13), or who had undergone AH without specific indication (Group III: 30 cycles in 22) from January, 1995 to Februry, 1996, and the outcomes of AH were analyzed according to pregnancy rate. The number of oocytes retrieved after controlled ovarian hyperstimulation (COH) was $9.9{\pm}7.1$ in Group I, $11.5{\pm}4.5$ in Group II, and $7.9{\pm}6.4$ in Group III. The number of embryos transferred after AH was $4.7{\pm}1.8$ in Group I, $5.3{\pm}1.3$ in Group II, and $3.5{\pm}2.4$ in Group III. The mean cumulative embryo score (CES) was $56.8{\pm}30.0$ in Group I, $76.1{\pm}35.9$ in Group II, and $38.5{\pm}29.9$ in Group III. The overall clinical pregnancy rate per cycle and per patient was 12.7% (9/71) and 16.7% (9/54) in Group I, 33.3% (5/15) and 38.5% (5/13) in Group II, and 6.7% (2/30) and 9.1% (2/22) in Group III, respectively. There were significant differences in the numbers of oocytes retrieved and embryos transferred, CES, and the clinical pregnancy rate per cycle among three groups. There was a significant inverse correlation between basal serum FSH level and CES, and no pregnancy occurred in patients with CES less than 20. In conclusion, AH of human embryos with PZD prior to ET has improved the implantation and pregnancy rates in IVF-ET patients with the past history of repeated failures, especially in spite of transfer of embryos with good quality, and AH will provide a range of novel techniques which may contribute much to effective management of infertile couples.